Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Chemo-senolytic therapeutic potential against angiosarcoma

ABSTRACT: Chemo-senolytic therapeutic potential against angiosarcoma

PROVIDER: PRJNA1030406 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR26453957.fastq.gz	Fastqsanger.gz
	SRR26453958.fastq.gz	Fastqsanger.gz
	SRR26453959.fastq.gz	Fastqsanger.gz
	SRR26453960.fastq.gz	Fastqsanger.gz
	SRR26453961.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 13

Similar Datasets

Chemo-senolytic therapeutic potential against angiosarcoma

Project description:Angiosarcoma is an aggressive soft-tissue sarcoma with a poor prognosis. Chemotherapy for this cancer typically employs paclitaxel, one of the taxanes (genotoxic drugs), although it has a limited effect due to chemoresistance for prolonged treatment. Here we examine a new angiosarcoma treatment approach that combines chemotherapeutic and senolytic agents. We first find that the chemotherapeutic drugs, cisplatin and paclitaxel, efficiently induce cellular senescence of angiosarcoma cells. Subsequent treatment with a senolytic agent, ABT-263, eliminates senescent cells through the activation of the apoptotic pathway. In addition, expression analysis indicates that senescence-associated secretory phenotype (SASP) genes are activated in senescent angiosarcoma cells and that ABT-263 treatment eliminates senescent cells expressing genes in the type-I interferon (IFN-I) pathway. Moreover, we show that cisplatin treatment alone requires a high dose to remove angiosarcoma cells, whereas a lower dose of cisplatin is sufficient to induce senescence, followed by the elimination of senescent cells by senolytic treatment. This study sheds light on a potential therapeutic strategy against angiosarcoma by combining a relatively low dose of cisplatin with the ABT-263 senolytic agent, which can help ease the deleterious side effects of chemotherapy.

2024-03-23 | GSE245935 | GEO

miRNA expression profile in angiosarcoma

Project description:We first use microRNA expression profiles to find miRNA expression signatures in 3 cases of human angiosarcoma and capillary hemangiomauman, then RT-PCR for large sample verification. Through the bioinformatics prediction of its target genes, we study its function and aim to find the new molecular markers and therapeutic targets. We identified the miRNA expression signatures in human angiosarcomas and capillary hemangiomas by using microRNA expression profiles

2015-02-06 | E-GEOD-65657 | biostudies-arrayexpress

miRNA expression profile in angiosarcoma

2015-02-06 | GSE65657 | GEO

Angiosarcoma gene expression

Project description:A comparison of gene expression in OCT frozen human angiosarcoma compared with OCT frozen normal mesenchymal tissues

2013-10-21 | GSE44115 | GEO

Gene expression of human angiosarcoma

Project description:Gene expression profiling of human angiosarcoma samples was performed using the NanoString Human nCounter PanCancer IO 360 Panel

2023-05-03 | GSE226338 | GEO

Prophilactic and long-lasting efficacy of senolytic CAR T cells against age-related metabolic dysfunction.

Project description:Senescent cells accumulate in organisms over time as a result of tissue damage and impaired immune surveillance and are thought to contribute to age-related tissue decline1,2. In agreement, genetic ablation studies reveal that elimination of senescent cells from aged tissues can ameliorate various age-related pathologies, including metabolic dysfunction and decreased physical fitness3-7. While small-molecule drugs capable of eliminating senescent cells (known as ‘senolytics’) partially replicate these phenotypes, many have uncertain mechanisms of action and all require continuous administration to be effective. As an alternative approach, we previously developed a cell-based senolytic therapy based on chimeric antigen receptor (CAR) T cells targeting uPAR, a cell-surface protein upregulated on senescent cells, and showed these can safely and efficiently eliminate senescent cells in young animals and reverse liver fibrosis8. We now show that uPAR-positive senescent cells accumulate during physiological aging and that they can be safely targeted with senolytic CAR T cells in aged animals. Treatment with anti uPAR CAR T cells ameliorates metabolic dysfunction by improving glucose tolerance and exercise capacity in physiological aging as well as in a model of metabolic syndrome. Importantly, the beneficial effects of senolytic CAR T cells are long lasting; single administration of a low dose is sufficient to achieve long-term therapeutic and preventive effects.

2023-12-08 | GSE243616 | GEO

Genome-wide analysis of the effects of propranolol on angiosarcoma tumor cells

2013-06-01 | GSE42534 | GEO

Genome-wide analysis of the effects of propranolol on angiosarcoma tumor cells

Project description:Analysis of the effects of 4 hr and 24 hr propranolol treatment on gene expression of SVR mouse angiosarcoma cells. The hypothesis tested in the present study was that inhibiton of beta adrenergic receptor signaling could ablate the oncogenic properties of angiosarcoma cells. Results provide important information of the response of angiosarcoma cells to ablated beta adrenergic receptor signaling. The total RNA was obtained from mouse angiosarcoma cells cultured in monolayer at 0, 4, and 24 hrs of 50 micromolar propranolol treatment. Illumina microarrays were performed to determine the whole genome expression changes following treatment.

2013-06-01 | E-GEOD-42534 | biostudies-arrayexpress

Gene expression of human angiosarcoma and correlation with treatment outcomes

Project description:Gene expression profiling of human angiosarcoma samples was performed using the NanoString Human nCounter PanCancer IO 360 Panel

2020-12-01 | GSE162370 | GEO

Gene expression of human angiosarcoma

Project description:Gene expression of human angiosarcoma

| PRJNA939728 | ENA